NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 230 filers reported holding NOVOCURE LTD in Q3 2023. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,557,215 | -45.4% | 344,100 | +40.4% | 0.51% | -54.6% |
| Q2 2023 | $10,171,650 | +30.1% | 245,100 | +88.5% | 1.13% | +39.6% |
| Q1 2023 | $7,818,200 | +747.0% | 130,000 | +879.3% | 0.81% | +462.5% |
| Q2 2022 | $923,000 | -35.5% | 13,275 | -23.2% | 0.14% | -22.2% |
| Q1 2022 | $1,431,000 | -14.4% | 17,275 | -22.4% | 0.18% | +10.8% |
| Q4 2021 | $1,672,000 | -47.2% | 22,275 | -18.3% | 0.17% | -66.2% |
| Q3 2021 | $3,169,000 | -85.6% | 27,275 | -72.4% | 0.49% | -85.4% |
| Q2 2021 | $21,955,000 | +556.0% | 98,975 | +290.8% | 3.38% | +459.9% |
| Q1 2021 | $3,347,000 | -22.6% | 25,325 | +1.3% | 0.60% | +5.6% |
| Q4 2020 | $4,326,000 | -25.8% | 24,999 | -52.3% | 0.57% | -81.5% |
| Q3 2020 | $5,830,000 | +74.3% | 52,377 | -7.1% | 3.09% | +62.1% |
| Q2 2020 | $3,344,000 | +787.0% | 56,397 | +907.6% | 1.91% | +334.2% |
| Q1 2020 | $377,000 | – | 5,597 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |